ACT Genomics Completed Another Round of Equity Financing


ACT Genomics is pleased to announce the completion of the latest round of equity financing from a group of international investors co-led by CLSA Capital Partners.

"New capital from this round of investment will support ACTG's strategic plan to strengthen our footprints and capabilities across the Pan-Asia region," said by Dr. Hua Chien Chen, Co-Founder and CEO of ACTG. "ACTG will continue its business expansion including the establishment of additional CAP-accredited NGS laboratories in Hong Kong, new products research and development, expansion of clinical services operations in Asia, and drug development collaboration with global and regional bio-pharmaceutical companies."